ONVO - オ―ガノボ・ホ―ルディングス (Organovo Holdings Inc.) オ―ガノボ・ホ―ルディングス

 ONVOのチャート


 ONVOの企業情報

symbol ONVO
会社名 Organovo Holdings Inc (オ―ガノボ・ホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オルガノボ・ホールディングス(Organovo Holdings Inc.)は機能的なヒト組織の開発・商業化を主とする初期の商業的段階の企業である。同社は主に、プラットフォーム技術を利用して3次元(3D)で人間の組織構築物を作る。同社は主に製品の開発を行う。その製品は、予測毒性学、吸収、分布、代謝、排泄(ADME)、薬物代謝および薬物動態(DMPK)における応用を含む薬物効果の前臨床評価に使用される3Dヒト組織、創薬・開発用の人間の生物学または疾患の生きた動的モデルとしてのカスタマイズされたヒト組織、並びにバイパス移植用の血管、神経損傷修復用の神経移植片、および損傷した組織および器官の修復または交換のための機能的組織パッチなどの臨床用途の三次元ヒト組織を含む。   オ―ガノボ・ホ―ルディングスは米国のバイオテクノロジ―企業。人間の組織や器官を3Dバイオプリンティング技術により生成し、変質またはダメ―ジを受けたヒト細胞の治療の研究開発・商業化に従事。生きた細胞のバイオインクと適合性のあるハイドロゲルを利用する同社技術の3Dバイオプリンタ―「ノボジェン」を開発。本社はカリフォルニア州サンディエゴ。   Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded in April 2007 and is headquartered in San Diego, CA.
本社所在地 6275 Nancy Ridge Drive Suite 110 San Diego CA 92121 USA
代表者氏名 Taylor J. Crouch テイラーJ.クラウチ
代表者役職名 President Chief Executive Officer
電話番号 +1 858-224-1000
設立年月日 40148
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 75人
url www.organovo.com
nasdaq_url https://www.nasdaq.com/symbol/onvo
adr_tso
EBITDA EBITDA(百万ドル) -31.41940
終値(lastsale) 1.12
時価総額(marketcap) 127063270.88
時価総額 時価総額(百万ドル) 123.65980
売上高 売上高(百万ドル) 4.30200
企業価値(EV) 企業価値(EV)(百万ドル) 84.04680
当期純利益 当期純利益(百万ドル) -32.11700
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 Organovo Holdings Inc revenues decreased 30% to $689K. Net loss decreased 27% to $7.4M. Revenues reflect Products and services decrease of 42% to $546K Collaborations and licenses decrease of 7% to $43K. Lower net loss reflects Research and development expenses - Bala decrease of 32% to $3.2M (expense) Stock-based Compensation in SGA. decrease of 37% to $1.1M (expense) selling.

 ONVOのテクニカル分析


 ONVOのニュース

   Why Organovo Stock Continues to Drop  2020/04/16 20:45:29 Nanalyze
We’ve been writing about disruptive technologies like 3D bioprinting for the past seven years now, and one stock that always seems to be going nowhere fast is Organovo (ONVO). In order to understand why Organovo stock continues to drop, we need to start from the beginning. The Origins of Organovo The story begins in 2010 […]
   BRIEF-Organovo Announces Termination Of Merger Agreement With Tarveda Therapeutics  2020/04/07 21:30:47 Reuters
Organovo Holdings Inc:
   Tarveda Therapeutics Provides Update on Proposed Merger with Organovo  2020/04/07 21:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics announces that the proposed merger agreement with Organovo Holdings, Inc. has been terminated.
   Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement  2019/12/16 12:00:00 Business Wire
SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--Organovo Holdings, Inc. and Tarveda Therapeutics, Inc. announce that they have entered into a definitive merger agreement.
   Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates  2019/08/09 00:50:06 Zacks Investment Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Why Organovo Stock Continues to Drop  2020/04/16 20:45:29 Nanalyze
We’ve been writing about disruptive technologies like 3D bioprinting for the past seven years now, and one stock that always seems to be going nowhere fast is Organovo (ONVO). In order to understand why Organovo stock continues to drop, we need to start from the beginning. The Origins of Organovo The story begins in 2010 […]
   BRIEF-Organovo Announces Termination Of Merger Agreement With Tarveda Therapeutics  2020/04/07 21:30:47 Reuters
Organovo Holdings Inc:
   Tarveda Therapeutics Provides Update on Proposed Merger with Organovo  2020/04/07 21:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics announces that the proposed merger agreement with Organovo Holdings, Inc. has been terminated.
   Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement  2019/12/16 12:00:00 Business Wire
SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--Organovo Holdings, Inc. and Tarveda Therapeutics, Inc. announce that they have entered into a definitive merger agreement.
   Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates  2019/08/09 00:50:06 Zacks Investment Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Why Organovo Stock Continues to Drop  2020/04/16 20:45:29 Nanalyze
We’ve been writing about disruptive technologies like 3D bioprinting for the past seven years now, and one stock that always seems to be going nowhere fast is Organovo (ONVO). In order to understand why Organovo stock continues to drop, we need to start from the beginning. The Origins of Organovo The story begins in 2010 […]
   BRIEF-Organovo Announces Termination Of Merger Agreement With Tarveda Therapeutics  2020/04/07 21:30:47 Reuters
Organovo Holdings Inc:
   Tarveda Therapeutics Provides Update on Proposed Merger with Organovo  2020/04/07 21:00:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics announces that the proposed merger agreement with Organovo Holdings, Inc. has been terminated.
   Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement  2019/12/16 12:00:00 Business Wire
SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--Organovo Holdings, Inc. and Tarveda Therapeutics, Inc. announce that they have entered into a definitive merger agreement.
   Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates  2019/08/09 00:50:06 Zacks Investment Research
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オ―ガノボ・ホ―ルディングス ONVO Organovo Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)